These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 22541836

  • 1. The concentration-dependent binding of linagliptin (BI 1356) and its implication on efficacy and safety.
    Wright S, Singh RP, Retlich S, Graefe-Mody U, Derendorf H.
    Int J Clin Pharmacol Ther; 2012 May; 50(5):323-30. PubMed ID: 22541836
    [Abstract] [Full Text] [Related]

  • 2. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA.
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
    Retlich S, Duval V, Ring A, Staab A, Hüttner S, Jungnik A, Jaehde U, Dugi KA, Graefe-Mody U.
    Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetic/pharmacodynamic analysis of the DPP-4 inhibitor linagliptin in Japanese patients with type 2 diabetes mellitus.
    Tadayasu Y, Sarashina A, Tsuda Y, Tatami S, Friedrich C, Retlich S, Staab A, Takano M.
    J Pharm Pharm Sci; 2013 Dec; 16(5):708-21. PubMed ID: 24393553
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.
    Friedrich C, Glund S, Lionetti D, Kissling CJ, Righetti J, Patel S, Graefe-Mody U, Retlich S, Woerle HJ.
    Br J Clin Pharmacol; 2013 Sep; 76(3):445-54. PubMed ID: 23331248
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
    Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA.
    Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
    [Abstract] [Full Text] [Related]

  • 11. Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
    Kalra S, Unnikrishnan AG, Agrawal N, Singh AK.
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):197-202. PubMed ID: 21913883
    [Abstract] [Full Text] [Related]

  • 12. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
    Deacon CF, Holst JJ.
    Expert Opin Investig Drugs; 2010 Jan; 19(1):133-40. PubMed ID: 19947894
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
    Scheen AJ.
    Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1561-76. PubMed ID: 22022857
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects.
    Graefe-Mody U, Rose P, Ring A, Zander K, Iovino M, Woerle HJ.
    Drug Metab Pharmacokinet; 2011 Dec; 26(2):123-9. PubMed ID: 21084763
    [Abstract] [Full Text] [Related]

  • 19. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
    Barnett AH.
    Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.